Robert W. Baird reiterates its Outperform rating on Array BioPharma (Nasdaq: ARRY).

The firm said it is "incrementally positive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE